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Abstract
Introduction: No consensus exists for post-hepatectomy venous thromboembolic (VTE) prophylaxis.
Factors impacting VTE prophylaxis patterns among hepato-pancreato-biliary (HPB) surgeons were
defined.
Method: Surgeons were invited to complete a web-based survey on VTE prophylaxis. The impact of
physician and clinical factors was analysed.
Results: Two hundred responses were received. Most respondents were male (91%) and practiced at
academic centres (88%) in the United States (80%). Surgical training varied: HPB (24%), transplantation
(24%), surgical oncology (34%), HPB/transplantation (13%), or no specialty (5%). Respondents estimated
VTE risk was higher after major (6%) versus minor (3%) resections. Although 98% use VTE prophylaxis,
there was considerable variability: sequential compression devices (SCD) (91%), unfractionated heparin
Q12h (31%) and Q8h (32%), and low-molecular weight heparin (39%). While 88% noted VTE prophylaxis
was not impacted by operative indication, 16% stated major resections reduced their VTE prophylaxis.
Factors associated with the decreased use of pharmacologic prophylaxis included: elevated international
normalized ratio (INR) (74%), thrombocytopaenia (63%), liver insufficiency (58%), large EBL (46%) and
complications (8%). Forty-seven per cent of respondents wait until ≥post-operative day 1 (POD1) and
35% hold pharmacologic VTE prophylaxis until no signs of coagulopathy. A minority (14%) discharge
patients on pharmacologic prophylaxis. While 81% have institutional VTE guidelines, 79% believe
hepatectomy-specific guidelines would be helpful.
Conclusion: There is considerable variation regarding VTE prophylaxis among liver surgeons. While
most HPB surgeons employ VTE prophylaxis, the methods, timing and purported contraindications differ
significantly.
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Introduction
The development of venous thromboembolism (VTE) in the peri-
operative period can be a devastating complication with high
morbidity and mortality. Strategies to prevent the development of
VTE include sequential compression devices (SCD) and
pharmacologic VTE prophylaxis. The use of pharmacologic VTE
prophylaxis can reduce the incidence of deep vein thrombosis
(DVT) and (pulmonary embolism) PE by about 75% among
general surgery patients.1,2 For the majority of abdominal opera-
tions, peri-operative pharmacological VTE prophylaxis is now
considered the standard of care for patients with a moderate-to-
high risk of developing a VTE.3,4 Most patients undergoing a liver
resection would be considered moderate-to-high risk,5 as VTE
within 90 days of a hepatic resection has been reported to occur in
nearly 1 in 12 patients.6,7 Liver surgeons, however, are often
worried about the potential for post-operative haemorrhage after
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a hepatectomy and may not be inclined to utilize peri-operative
pharmacological VTE prophylaxis.
The decision whether to employ peri-operative VTE prophy-
laxis, and the type of prophylaxis (e.g. SCDs vs. pharmacologic
VTE prophylaxis), often relies on the individual surgeons assess-
ment of the relative risk of developing a VTE versus post-operative
haemorrhage for a particular patient and operation. Further com-
plicating a liver surgeon’s decision on prophylaxis are the numer-
ous available types of VTE prophylaxis [SCD, unfractionated
heparin (UFH), low-molecular-weight heparin (LMWH)], as
well as the varied dosing interval associated with pharmacolo-
gical VTE prophylaxis (e.g. q 12 h vs. q 8 h). Historically, some
surgeons have perceived the risk of VTE after a liver resection
to be lower than for other major abdominal procedures owing to
transient liver dysfunction sometimes reflected in an increased
prothrombin time and international normalized ratio (INR).
Barton et al. 8 found, however, that in spite of elevated INR
values, thromboelastography actually demonstrated a brief hyper-
coagulable state after a liver resection. Other studies have similarly
noted that VTE risk may actually increase with more extensive
hepatic resections even in the setting of increased post-operative
INR levels.9,10 Even patients suffering from chronic liver insuffi-
ciency do not appear to be anticoagulated based on elevated INR
levels and may actually be at an increased risk of VTE.11,12
Owing to a lack of data on VTE-related outcomes after a hepa-
tectomy, current practice guidelines regarding prophylaxis for
patients undergoing a liver resection remain unclear. While some
institutions have formalized ‘current best practices’ around
prophylaxis for VTE after a hepatic resection, other centres have
not. Although there is a perceived large amount of heterogeneity
in practice patterns among liver surgeons, the degree of this vari-
ability has not been previously defined or quantitated. In the
present study, we hypothesized that a wide array of factors might
influence the choice of whether to administer VTE prophylaxis
around the time of a hepatic resection. We sought to determine
current VTE prophylaxis patterns among practicing hepato-
pancreato-biliary (HPB) surgeons and define what clinical factors
impact their choice and timing of VTE prophylaxis.
Methods
Key clinical factors were incorporated into a 35-question survey
that was designed to evaluate current VTE prophylaxis patterns
among surgeons who perform liver surgery (Appendix S1). The
survey instrument was divided into three sections focused on data
collection regarding: (i) details on surgeon demographics and
training, (ii) surgeon perception and assessment of VTE risks,
practice patterns and opinions on VTE prophylaxis utilization,
and (iii) VTE guidelines. In particular, the respondent was asked
which VTE prophylaxis (s)he would recommend around the time
of liver resection, when prophylaxis is typically initiated, as well
as the type of prophylaxis preferred (e.g. SCD, UFH, LMWH).
In addition, specific questions were aimed at identifying which
clinical factors the respondent utilized in making decisions
regarding VTE prophylaxis at the time of liver resection. The
clinical factors which we asked respondents to evaluate for a
potential impact on VTE prophylaxis included: a prior history of
DVT/ PE, hypercoaguable diagnosis, obesity, cancer diagnosis,
co-morbidities, combined operations, post-operative complica-
tions, elevated INR values, liver insufficiency, large volume blood
loss and major versus minor liver resections. All co-authors
reviewed the survey for validity and we did a small pilot of sending
the survey to all HPB faculties in the participating departments.
Invitations to take the survey were sent by e-mail to surgical
members of the Americas Hepato-Pancreatobiliary Association,
International Hepato-Pancreatobiliary Association and Surgical
Society of the Alimentary Tract, with self-reported interests in
liver surgery; e-mail addresses were obtained from publicly avail-
able sources such as web sites and publications in the field.13,14
Response to the survey was voluntary and anonymous; no finan-
cial incentive was offered to encourage participation. After the
initial distribution of the survey, we scheduled three automatic
email reminders at 2-week intervals to all non-responders, which
were coded with a unique identification number. The survey was
sent to 414 email addresses and opening the email was considered
confirmation that the email address was correct and the survey
was viewed. The questionnaire was available online through
QuestionPro (a survey engine). The study protocol and survey
instrument were approved by the Johns Hopkins University
School of Medicine Institutional Review Board.
35-question survey
Descriptive statistics were compared using Fisher’s exact test, the
rank-sum test, or the Kruskal–Wallis test, as appropriate. Choice
data were analysed using multinomial logistic regression models
with robust variance estimates, yielding odds ratios (OR) and 95%
confidence intervals (95% CI) that reflect the change in the odds of
choosing a particular therapy over an alternative. For each of the 10
different VTE prophylaxis patterns examined a separate regression
model was created that included factors of clinical significance
including: gender, country of practice, private or community hos-
pital vs. academic or university hospital, fellowship, years after
training and practice pattern. All tests of statistical significance
were two-sided, and statistical significance was established at P <
0.05. Statistical analyses were performed using Stata/MP 10.1 for
Windows (StataCorp LP, College Station, TX, USA).
Results
The email was sent to 414 recipients, 297 recipients opened the
email, and 200 responded. Demographic and practice character-
istics of the respondents are given in Table 1. The majority of
respondents (88%) practiced at academic centres, and 55% were
in practice ≥10 years. The overwhelming majority of respon-
dents were male (91%) and practiced in the United States (81%).
Surgical training varied: 34% surgical oncology, 24% transplant,
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24% HPB, 13% combined HPB/transplant and 5% no fellowship
training. Most respondents (67%) reported that the majority
(>50%) of their clinical practice involved HPB surgery. Respond-
ents reported performing a median of four [interquartile range
(IQR) 2–5] liver resections per month, with half (50%) of the
resections being major (≥3 segments) (IQR 34–70).
Responses to attitudinal questions of respondents regarding the
method and timing of VTE prophylaxis patterns were assessed.
The overwhelming majority (98%) of respondents routinely used
VTE prophylaxis. There was considerable variability, however,
regarding which VTE prophylaxis modalities were employed: 91%
SCD, 39% LMWH, 32% UFH every 8 h and 31% UFH every 12 h
(Table 2). When asked to assess the risk of VTE among patients
undergoing a liver resection, respondents had a variable estimate.
Specifically, 4% of respondents estimated the risk to be <1%,
whereas 69% estimated the risk at 1–6%, 17% at 7–9%, and 10%
thought the risk of VTE after liver resection was >10%. Of note,
respondents estimated the risk of VTE to be higher after a major
versus minor resection (mean estimated risk: 7% vs. 4%, respec-
tively; P < 0.001). In spite of this, 16% of respondents noted that
they were less likely to administer pharmacological VTE prophy-
laxis after a major resection compared with a minor resection. In
general, respondent estimates for VTE risk varied based on the
indication for surgery: benign (2%) vs. malignant (5%) disease
(P < 0.001). However, 88% of respondents stated that the likeli-
hood of administering pharmacological VTE prophylaxis did not
change based on the indication for surgical resection.
Factors that most respondents did state would increase their
likelihood of administering pharmacological VTE prophylaxis
after a hepatectomy included: a history of DVT/PE (89%), a
hypercoaguable diagnosis (88%), obesity (84%), multiple medical
co-morbidities (67%), combined operations (65%) and early
post-operative complications other than haemorrhage (38%)
(Fig. 1). In contrast, factors that influenced respondents to choose
not to use pharmacological VTE prophylaxis included: elevated
INR (74%), thrombocytopaenia (63%), liver insufficiency (58%),
large operative blood loss (46%) and an early post-operative com-
plication (7%) (Fig. 2). With regard to the timing of pharmaco-
logical VTE prophylaxis initiation, 47% of respondents reported
that they routinely waited until post-operative day (POD) 1 or
longer and 35% stated that they routinely hold pharmacological
VTE prophylaxis until there are no objective signs of
coagulopathy. While only 17% of respondents indicated that they
believe pharmacological VTE prophylaxis increased the risk of
post-operative bleeding, 15% stated that they have had at least one
bleeding complication that they believe was directly attributable
to pharmacological VTE prophylaxis administration. Among all
respondents, 28% reported that they believed routine administra-
tive of pharmacological VTE prophylaxis pre-operatively was
unnecessary; this proportion increased to 59% when respondents
were asked about patients undergoing only a minor liver resec-
tion. Twenty-two per cent of respondents stated that their VTE
prophylaxis pattern changed based on the extent of liver resection.
Table 1 Surgeon demographics and practice characteristics of
respondents (n = 200)
Characteristics Value, No. (%)
Male gender, No. (%) 181 (91)
Country, US, No.(%) 161 (81)
Fellowship, No.(%)
Surgical Oncology Fellowship 68 (34)
Hepato-Pancreato-Biliary Fellowship 48 (24)
Transplant Fellowship 48 (24)
Combined hepato-pancreato-biliary and
Transplant Fellowship
25 (13)
None 11 (6)
Years after completion of training, No.(%)
≤10 years 91 (46)
11–20 years 65 (33)
21–30 years 34 (17)
>30 years 10 (5)
Primary practice setting, No.(%)
Academic practice or university hospital staff 175 (88)
Private practice or community hospital staff 24 (12)
Hepato-pancreato-biliary practice
≥75% 93 (47)
50–74% 40 (20)
25–49% 34 (17)
<25% 33 (17)
Number of liver resection per month, median (IQR) 4 (2–5)
Major resection(≥3 segments), %, median (IQR) 50 (34–70)
IQR, interquartile range.
Table 2 Method and timing of respondents' VTE prophylaxis
patterns
Type of DVT/PE prophylaxis (multiple choice) No. (%)
Sequential compression devices 176 (91.2)
Low molecular weight heparin 76 (39.4)
Unfractionated heparin q8 hours 61 (31.6)
Unfractionated heparin q12 hours 59 (30.6)
Time of administering DVT/PE prophylaxis No. (%)
POD 0 103 (53.4)
POD ≥ 1 90 (46.6)
Hold administering of pharmacologic DVT/PE
prophylaxis until laboratory values demonstrate
no signs of coagulopathy or bleeding
(%)
Strongly agree and Agree 34.2
Neither agree nor disagree 13.8
Strongly disagree and Disagree 52.0
VTE, venous thromboembolic; DVT, deep vein thrombosis; PE,
pulmonary embolism, POD, post-operative day.
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Of note, 14% of respondents noted that they routinely discharge
patients home on pharmacological VTE prophylaxis after hepatic
resections.
Surgeon-specific factors were evaluated for differences in self-
reported practice patterns regarding thromboembolic prophy-
laxis. While there were no differences in timing of
pharmacological VTE prophylaxis associated with surgeon demo-
graphics or training experience, self-reported surgeon HPB
volume influenced pharmacological VTE prophylaxis practice
patterns. Compared with lower volume HPB surgeons, surgeons
who described their practice as >75% HPB estimated that the risk
of VTE was lower for both minor (5% vs. 3%, respectively;
P < 0.001) and major hepatectomies (8% vs. 6%, respectively;
P = 0.01) (Table 3). In addition, compared with lower volume
HPB surgeons, surgeons who self-reported a practice consisting
of >75% HPB cases stated using pharmacological VTE prophy-
laxis a mean duration of 1.5 days longer (4.6 vs. 6.1 days, P = 0.03)
after a liver resection. Attitudes towards pharmacological VTE
prophylaxis were also impacted by factors such as academic versus
community hospital status, as well as geographical location of
the provider. Specifically, surgeons who practiced in a community
setting were more likely to believe that the administration of
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pharmacological VTE prophylaxis increased the risk of post-
operative surgical bleeding (OR 6.77, 95% CI 2.66–17.22;
P < 0.001). Furthermore, surgeons practicing in the United States
were more likely to use SCD (OR 3.62, 95% CI 1.47–8.94;
P = 0.005), as well as UFH every 8 h as pharmacological VTE
prophylaxis (OR 4.80, 95% CI 1.62–14.17; P = 0.005). In contrast,
surgeons from the United States were less likely to report using
LMWH as pharmacological VTE prophylaxis (OR 0.38, 95% CI
0.19–0.77; P = 0.008). United States surgeons were also less likely
to report the practice of discharging patients home on pharma-
cological VTE prophylaxis after hepatic resections (OR 0.37, 95%
CI 0.15–0.87; P = 0.02).
Regarding general attitudes about VTE guidelines and practice
patterns at their hospital, 88% of respondents reported a belief
that a major variation in pharmacological VTE prophylaxis pat-
terns existed among HPB surgeons. Most respondents (81%)
indicated that their own institution had guidelines on VTE
prophylaxis and most surgeons (80%) reported adherence to
the recommended hospital guidelines. However, only 52% of
respondents believed that their institutional VTE guides were
actually based on data relevant for patients undergoing HPB
surgery and 79% of respondents stated that consensus guidelines
specific for a hepatectomy would be useful in their practice.
Discussion
Liver surgeons face a challenging dilemma in deciding on the
method and timing of VTE prophylaxis after a hepatectomy.
Several recent studies have demonstrated that the occurrence of
VTE after a hepatectomy is not uncommon and the incidence
ranges from 2.1% to 4.7%.6,9,10,15–18 In the past, liver surgeons have
been reluctant to initiate pharmacological prophylaxis because of
the perception that these patients may be at a lower risk of devel-
oping VTE events and a higher risk of post-operative bleeding
than other surgical procedures. However, a review of 5651 NSQIP
patients undergoing liver surgery revealed that the risk of VTE was
higher after major hepatic resections and outweighed the risk of
bleeding.10 In fact, these investigators found that patients who
experienced a VTE had a 30-day mortality of 7.4% versus 2.3% for
those patients who did not have a VTE event.10 The American
College of Chest Physicians has recommended the use of chemo-
prophylaxis over no prophylaxis in surgical patients of moderate-
to-high risk.3 In turn, based on the widely used and externally
validated Caprini risk scoring system, most patients undergoing
a liver resection would be considered moderate-to-high risk.5
However, owing to the perceived risk of possible peri-operative
bleeding after a hepatectomy, this recommendation is only grade
2C.19,20 Provider perceptions about these guideline recommenda-
tions, as well as surgeon VTE practice patterns, have been poorly
characterized. The current study is important because it utilized a
broad-based multi-institutional survey to define surgeon attitudes
and practices around VTE prophylaxis after a liver resection.
We found that considerable practice variation exists among liver
Table 3 Clinical factors associated with patterns of VTE prophylaxis
use among hepato-pancreato-biliary surgeons
Patterns of VTE prophylaxis OR 95% CI P-value
Hold prophylaxis administration until there
are no signs of coagulopathy
Clinical care >75% Ref
Clinical care ≤75% 0.55 0.30–1.01 0.05
Send patients home on pharmacological
prophylaxis
Non-US surgeon Ref – –
US surgeon 0.37 0.15–0.87 0.02
Clinical care >75% Ref
Clinical care ≤75% 3.82 1.54–9.48 0.004
Sequential compression
Non-US surgeon Ref – –
US surgeon 3.62 1.47–8.94 0.005
Unfractionated heparin q12
≤10 years after completion of training Ref – –
11–20 years 1.59 0.78–3.24 0.20
21–30 years 2.33 1.01–5.40 0.05
>30 years 1.43 0.34–6.02 0.63
Unfractionated heparin q8
Non-US surgeon Ref – –
US surgeon 4.80 1.62–14.17 0.005
≤10 years after completion of training Ref – –
11–20 years 0.37 0.18–0.75 0.01
21–30 years 0.29 0.11–0.76 0.01
>30 years 0.33 0.07–1.66 0.18
LMWH
Non-US surgeon Ref – –
US surgeon 0.38 0.19–0.77 0.008
Administering prophylaxis increases the risks
of surgical bleeding
Private practice or community hospital Ref – –
Academic practice or university hospital 0.15 0.06–0.38 <0.001
Postoperative prophylaxis is necessary
Major resection >51% Ref
Major resection ≤50% 0.22 0.08–0.62 0.004
All patients should receive prophylaxis
before and after liver resection
Non-US surgeon Ref – –
US surgeon 2.28 1.06–4.90 0.04
≤10 years after completion of training Ref – –
11–20 years 0.59 0.27–1.28 0.18
21–30 years 0.31 0.13–0.76 0.01
>30 years NA
Patients undergoing a minor liver resection
should receive both pre and post
operative prophylaxis
≤10 years after completion of training Ref – –
11–20 years 0.68 0.35–1.32 0.25
21–30 years 0.38 0.17–0.84 0.02
>30 years 0.24 0.06–1.02 0.05
Each of the 10 statistical regression models the same independent variables which
include gender, country of practice, private or community hospital vs. academic or
university hospital, fellowship, years after training, and practice pattern.
VTE, venous thromboembolic; LMWH, low-molecular-weight heparin; US, United
States; OR, odds ratio; CI, confidence interval.
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surgeons. Interestingly, while 98% of surgeons routinely use VTE
prophylaxis, the methods and timing of pharmacological VTE
prophylaxis varied significantly.
While most surgeons utilized SCDs (91%) in combination
with pharmacological VTE prophylaxis, some employed UFH
(61%) and others LMWH (39%). The reported high frequency
use of combined pharmacological VTE prophylaxis and SCDs in
our study is in agreement with current recommendations against
mechanical methods as monotherapy for cancer patients.21
Regarding the choice of pharmacological VTE prophylaxis, there
are three randomized trials comparing LMWH and UFH for
pharmacological VTE prophylaxis in cancer22,23 and colorectal
surgery24 patients, all of whom appear to show similar efficacy
with LMWH and UFH. However, meta-analyses evaluating differ-
ent dosing regimens of these drugs demonstrate that UFH given
every 8 h, as well as daily LMWH, are superior to UFH given
twice daily.2,25 This is noteworthy, because roughly one-third of
respondents are utilizing UFH twice daily.
There are no studies evaluating the optimal timing of pharma-
cological VTE prophylaxis for hepatectomies; however, current
international guidelines for patients undergoing cancer surgery
recommends initiation of pharmacological VTE prophylaxis
2–12 h pre-operatively.21 A large proportion of respondents do
not appear to be following these guidelines for patients undergo-
ing a hepatectomy; 47% of respondents stated that they routinely
wait until POD 1 and 35% until there are no signs of coagulopathy
before initiating pharmacological VTE prophylaxis. Similarly, in
spite of data to suggest that the risk of VTE remains elevated for at
least 12 weeks after surgery,3 only 14% of liver surgeons routinely
send patients home on pharmacological VTE prophylaxis. This
may be important because Tzeng et al. 17 found that 29% of all
VTE after a hepatectomy occurred post-discharge.
Based upon somewhat limited data, the authors currently ini-
tiate mechanical and pharmacological VTE prophylaxis within
2 h of incision and continue pharmacological VTE prophylaxis
for the duration of the hospitalization after a hepatectomy.
However, given the significant variation found in prophylaxis
patterns amongst liver surgeons in this survey, we sought to
identify factors that might influence provider decisions around
VTE administration. We found that significant practice variation
exists that is independent of post-graduate training and several
other demographical variables. Self-reported higher volume
HPB surgeons described the risk of VTE as lower, while stating
that they prescribe pharmacological VTE prophylaxis for a
longer duration than lower volume HPB surgeons. In addition,
surgeons in community practice were more likely to believe
that pharmacological VTE prophylaxis increased the risk of
bleeding after a hepatectomy. Interestingly, surgeons from
the United States more frequently used UFH for pharmacologi-
cal VTE prophylaxis and were less likely to continue therapy
post-discharge.
Our study had several limitations which should be considered.
First, the survey assessed stated preferences for VTE prophylaxis
among liver surgeons as opposed to their actual practice patterns.
There may be differences between a surgeon’s stated and actual
VTE prophylaxis pattern. Second, because we do not know
the characteristics of the non-respondents, we cannot verify
that the findings are representative of all surgeons performing
hepatectomies. We specifically targeted surgeons who had pub-
lically available email addresses, so our results may not be repre-
sentative of liver surgeons ‘at-large.’ However, the demographics of
respondents reflected a wide range of training backgrounds and
19% of respondents were from outside of the United States.
In conclusion, there is considerable practice variation regard-
ing VTE prophylaxis among liver surgeons. The vast majority
of surgeons agree that VTE events after a hepatectomy are not
uncommon and routinely employ VTE prophylaxis. However,
the methods, timing and purported contraindications to VTE
prophylaxis differ significantly among liver surgeons and are not
necessarily supported by the literature. Different VTE prophy-
laxis patterns appear independent of post-graduate training
and most demographic variables, but may be related to reported
volume of HPB surgery, practice setting and location. Our data
highlight the lack of consensus on the method and timing
of VTE prophylaxis after liver operations among practicing
surgeons.
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